JBIO Company Profile and Key Details

JBIO has shown sold momentum, gaining 10.03% over the past week and 62.75% over the past quarter, though year-to-date performance is down -1.17%. Short-term trend indicators are mixed aligned (SMA20 -2.42%, SMA50 -3.69%, SMA200 38.26%). The stock’s 14-day RSI is 48.59 (neutral), while the ATR of 1.32 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -17.79% below its high and over 121.78% above its low. Average 10-day trading volume of 1.90 million shares is significantly above the 3-month average of 925.82 thousand, indicating heightened recent market interest.

Jade Biosciences, Inc. generated EPS of -$11.36 over the past year. Five-year average earnings growth is -77.98%. Wall Street analysts project EPS growth of 69.31% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 13 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $74.00 to $17.00. The high target offers 236.82% upside. The low target suggests -22.62% downside. The mean target is $35.47. This offers 61.45% upside. Jade Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by 9.62%. The prior quarter beat by -75.56%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in March 27, 2025.

Jade Biosciences, Inc. last paid a dividend of 2.4 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.80. This means the shares are trading above this model’s fair value.

Jade Biosciences, Inc. (NASDAQ:JBIO) closed at $21.97 USD, gaining $2.52 (12.96%) from the previous close of $19.45. The stock is currently mid-range between its 52-week high and low $6.67 and $28.00. With a market capitalization of about $716.79 million, Jade Biosciences, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.45). Key stats such as the average daily volume over the past year has been around 900.36 thousand shares, trading with heavier-than-usual volume. Headquartered in Waltham, MA, Jade Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Tom Frohlich, the company employs approximately 50 people and listed since April 29, 2025. Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders.

Jade Biosciences, Inc. trades at a P/E ratio of -7.34, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.18 trading at moderately above to book value. The P/FCF stands at -6.0, also above market averages.

Our AI price prediction model suggests that Jade Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -26.67%, with price expected at $16.11 by July 06, 2026, within a range of $14.39 to $17.78 3-Month Outlook: Projected fall of -32.32%, reaching $14.87 by September 18, 2026, with a range of $14.60 to $15.14. 1-Year Outlook: Projected gain of 42.92%, with price at $31.40 by June 22, 2027, within a range of $30.69 to $32.27.

Jade Biosciences, Inc. (NASDAQ:JBIO) shares are flat -1.17% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Jade Biosciences, Inc. trading at a premium to the broader market with a P/E of -7.34. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $34.28, suggesting 56.03% upside. Our AI forecast model points to short-term weakness (-26.67% over two weeks), a medium-term fall (-32.32% over three months), and a longer-term gain (42.92% over one year), with expected trading ranges indicating moderate volatility.